Abstract

Duffy-binding protein (DBP) is the leading vaccine candidate for Plasmodium vivax malaria. Two studies express and characterise the first human monoclonal antibodies against DBP, induced by natural infection and vaccination, showing they have in vitro functional activity but target different conserved epitopes.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.